Establishment and Comprehensive Molecular Characterization of an Immortalized Glioblastoma Cell Line from a Brazilian Patient

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Fernanda F. da
dc.contributor.authorLUPINACCI, Fernanda C. S.
dc.contributor.authorELIAS, Bruno D. S.
dc.contributor.authorBESERRA, Adriano O.
dc.contributor.authorSANEMATSU, Paulo
dc.contributor.authorROFFE, Martin
dc.contributor.authorKULIKOWSKI, Leslie D.
dc.contributor.authorCOSTA, Felipe D'almeida
dc.contributor.authorSANTOS, Tiago G.
dc.contributor.authorHAJJ, Glaucia N. M.
dc.date.accessioned2023-12-15T18:59:01Z
dc.date.available2023-12-15T18:59:01Z
dc.date.issued2023
dc.description.abstractGlioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with few effective treatment strategies. The research on the development of new treatments is often constrained by the limitations of preclinical models, which fail to accurately replicate the disease's essential characteristics. Herein, we describe the obtention, molecular, and functional characterization of the GBM33 cell line. This cell line belongs to the GBM class according to the World Health Organization 2021 Classification of Central Nervous System Tumors, identified by methylation profiling. GBM33 expresses the astrocytic marker GFAP, as well as markers of neuronal origin commonly expressed in GBM cells, such as beta III-tubulin and neurofilament. Functional assays demonstrated an increased growth rate when compared to the U87 commercial cell line and a similar sensitivity to temozolamide. GBM33 cells retained response to serum starvation, with reduced growth and diminished activation of the Akt signaling pathway. Unlike LN-18 and LN-229 commercial cell lines, GBM33 is able to produce primary cilia upon serum starvation. In summary, the successful establishment and comprehensive characterization of this GBM cell line provide researchers with invaluable tools for studying GBM biology, identifying novel therapeutic targets, and evaluating the efficacy of potential treatments.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2020/14045-0]
dc.identifier.citationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, n.21, article ID 15861, 14p, 2023
dc.identifier.doi10.3390/ijms242115861
dc.identifier.eissn1422-0067
dc.identifier.issn1661-6596
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57608
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectglioblastomaeng
dc.subjectcell lineseng
dc.subjectprimary ciliaeng
dc.subjectAkteng
dc.subjectmTOReng
dc.subjectcopy number variationeng
dc.subjectmethylation profileeng
dc.subject.othercentral-nervous-systemeng
dc.subject.otherprimary ciliaeng
dc.subject.otherexpressioneng
dc.subject.otherclassificationeng
dc.subject.otherciliogenesiseng
dc.subject.othersensitivityeng
dc.subject.othercancereng
dc.subject.othertumorseng
dc.subject.otherstemeng
dc.subject.wosBiochemistry & Molecular Biologyeng
dc.subject.wosChemistry, Multidisciplinaryeng
dc.titleEstablishment and Comprehensive Molecular Characterization of an Immortalized Glioblastoma Cell Line from a Brazilian Patienteng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalSILVA, Fernanda F. da:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.author.externalLUPINACCI, Fernanda C. S.:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.author.externalELIAS, Bruno D. S.:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.author.externalBESERRA, Adriano O.:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.author.externalSANEMATSU, Paulo:AC Camargo Canc Ctr, Neurosurg Dept, BR-01509010 Sao Paulo, Brazil
hcfmusp.author.externalROFFE, Martin:Childrens Hosp Eastern Ontario Res Inst, Ottawa, ON K1H 8L1, Canada
hcfmusp.author.externalCOSTA, Felipe D'almeida:AC Camargo Canc Ctr, Dept Anat Pathol, BR-01509010 Sao Paulo, Brazil
hcfmusp.author.externalSANTOS, Tiago G.:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.author.externalHAJJ, Glaucia N. M.:AC Camargo Canc Ctr, CIPE, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; Natl Inst Sci & Technol Oncogen INCITO, BR-01509900 Sao Paulo, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcLESLIE DOMENICI KULIKOWSKI
hcfmusp.description.articlenumber15861
hcfmusp.description.issue21
hcfmusp.description.volume24
hcfmusp.origemWOS
hcfmusp.origem.pubmed37958846
hcfmusp.origem.scopus2-s2.0-85176578026
hcfmusp.origem.wosWOS:001100326900001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAllen M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6853eng
hcfmusp.relation.referenceAlvarez-Satta M, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918801169eng
hcfmusp.relation.referenceAnvarian Z, 2019, NAT REV NEPHROL, V15, P199, DOI 10.1038/s41581-019-0116-9eng
hcfmusp.relation.referenceBaronchelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057462eng
hcfmusp.relation.referenceBashir T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047741eng
hcfmusp.relation.referenceBasten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046-2530-2-2eng
hcfmusp.relation.referenceBerger TR, 2022, JAMA ONCOL, V8, P1493, DOI 10.1001/jamaoncol.2022.2844eng
hcfmusp.relation.referenceBorowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998eng
hcfmusp.relation.referenceBrennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034eng
hcfmusp.relation.referenceCapper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000eng
hcfmusp.relation.referenceChen CH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.621432eng
hcfmusp.relation.referenceCruvinel-Carloni A, 2017, TRANSL CANCER RES, V6, P332, DOI 10.21037/tcr.2017.03.32eng
hcfmusp.relation.referenceDavis B, 2016, NEURO-ONCOLOGY, V18, P350, DOI 10.1093/neuonc/nov143eng
hcfmusp.relation.referenceGhandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3eng
hcfmusp.relation.referenceGradilone SA, 2013, CANCER RES, V73, P2259, DOI 10.1158/0008-5472.CAN-12-2938eng
hcfmusp.relation.referenceGrube S, 2021, CANCER REP-US, V4, DOI 10.1002/cnr2.1324eng
hcfmusp.relation.referenceHan YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020eng
hcfmusp.relation.referenceHassounah NB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068521eng
hcfmusp.relation.referenceHoang-Minh Lan B, 2018, Cilia, V7, P6, DOI 10.1186/s13630-018-0060-5eng
hcfmusp.relation.referenceHoang-Minh LB, 2016, TRANSL ONCOL, V9, P392, DOI 10.1016/j.tranon.2016.08.006eng
hcfmusp.relation.referenceHoang-Minh LB, 2016, ONCOTARGET, V7, P7029, DOI 10.18632/oncotarget.6854eng
hcfmusp.relation.referenceKaur Gurvinder, 2012, Spermatogenesis, V2, P1eng
hcfmusp.relation.referenceLee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030eng
hcfmusp.relation.referenceLi AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541-7786.MCR-07-0280eng
hcfmusp.relation.referenceLiu HQ, 2018, NAT REV CANCER, V18, P511, DOI 10.1038/s41568-018-0023-6eng
hcfmusp.relation.referenceLoskutov YV, 2018, ONCOGENE, V37, P1457, DOI 10.1038/s41388-017-0049-3eng
hcfmusp.relation.referenceLouis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106eng
hcfmusp.relation.referenceMachado LE, 2018, J HISTOCHEM CYTOCHEM, V66, P403, DOI 10.1369/0022155417750838eng
hcfmusp.relation.referenceMellinghoff IK, 2023, NEW ENGL J MED, V389, P589, DOI 10.1056/NEJMoa2304194eng
hcfmusp.relation.referenceMoser JJ, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-40eng
hcfmusp.relation.referenceMoser JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-448eng
hcfmusp.relation.referenceOstrom QT, 2019, NEURO-ONCOLOGY, V21, pV1, DOI 10.1093/neuonc/noz150eng
hcfmusp.relation.referenceSarkisian MR, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00055eng
hcfmusp.relation.referenceSarkisian MR, 2014, J NEURO-ONCOL, V117, P15, DOI 10.1007/s11060-013-1340-yeng
hcfmusp.relation.referenceSeeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290eng
hcfmusp.relation.referenceStupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330eng
hcfmusp.relation.referenceWankowicz P, 2020, ARCH MED SCI, V16, P481, DOI 10.5114/aoms.2020.92857eng
hcfmusp.relation.referenceXu ZY, 2018, METHODS MOL BIOL, V1741, P183, DOI 10.1007/978-1-4939-7659-1_14eng
hcfmusp.relation.referenceYan T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-524eng
hcfmusp.relation.referenceYu W, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01547eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationa248ef47-b0c3-4941-ba03-78adb1cf4766
relation.isAuthorOfPublication.latestForDiscoverya248ef47-b0c3-4941-ba03-78adb1cf4766
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_SILVA_Establishment_and_Comprehensive_Molecular_Characterization_of_an_Immortalized_2023.PDF
Tamanho:
2.29 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/36